Skip to main content
. 2019 May 11;11(5):651. doi: 10.3390/cancers11050651

Table 1.

Current clinical trials using oncolytic HSV (as listed on ClinicalTrials.gov, accessed April 2019).

HSV Study Identifier Phase
OH2 Phase I Study of OH2 Injection, an Oncolytic Type 2 Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor, in Malignant Solid Tumors NCT03866525 1
rRp450 rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors NCT01071941 1
Orien
X010
Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010), Standard Injection in Tumor, Treatment Scheme Failed, M1c IV Period, Malignant Melanoma Spread to the Liver, Open I-c Phase of Clinical Trial NCT03048253 1c
M032 A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma NCT02062827 1
C134 A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients With Recurrent Malignant Glioma NCT03657576 1
G207 Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors NCT03911388 1
G207 Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors NCT02457845 1
T-VEC A Phase I, Open Label, Single Arm, Single Centre Study to Evaluate Mechanism of Action of Talimogene Laherparepvec (T-VEC) in Locally Advanced Non-melanoma Skin Cancer NCT03458117 1
T-VEC A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer NCT02779855 1/2
T-VEC A Phase II Study Using Talimogene Laherparepvec as a Single Agent for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence NCT02658812 2
T-VEC A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors NCT02978625 2
T-VEC A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Paclitaxel or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-Negative Breast Cancer With Evidence of Injectable Disease in the Locoregional Area NCT03554044 1b
T-VEC A Phase II Study of Combining Talimogene Laherparepvec T-VEC (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy NCT02965716 2
T-VEC A Phase I Study of Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum NCT03300544 1